Mathias Chamaillard

List of Publications by Year
in descending order

Version: 2024-02-01

109 papers	25,218 citations	47006 47 h-index	29157 104 g-index
113 all docs	113 docs citations	113 times ranked	25994 citing authors

#	Article	IF	Citations
1	The role of the gut microbiome on radiation therapy efficacy and gastrointestinal complications: A systematic review. Radiotherapy and Oncology, 2021, 156, 1-9.	0.6	44
2	Role of NLRs in the Regulation of Type I Interferon Signaling, Host Defense and Tolerance to Inflammation. International Journal of Molecular Sciences, 2021, 22, 1301.	4.1	19
3	NOD1 sensing of house dust miteâ€“derived microbiota promotes allergic experimental asthma. Journal of Allergy and Clinical Immunology, 2021, 148, 394-406.	2.9	10
4	Lactobacillus reuteri 5454 and Bifidobacterium animalis ssp. lactis 5764 improve colitis while differentially impacting dendritic cells maturation and antimicrobial responses. Scientific Reports, 2020, 10, 5345.	3.3	39
5	NOD2 Influences Trajectories of Intestinal Microbiota Recovery After Antibiotic Perturbation. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 365-389.	4.5	19
6	The Ubiquitin Code of NODs Signaling Pathways in Health and Disease. Frontiers in Immunology, 2019, 10, 2648.	4.8	10
7	The regenerating family member 3 Î² instigates IL-17A-mediated neutrophil recruitment downstream of NOD1/2 signalling for controlling colonisation resistance independently of microbiota community structure. Gut, 2019, 68, 1190-1199.	12.1	14
8	Integrin a6 loss promotes colitis-associated colorectal cancer. Response to: â€œIntegrin a6 variants and colorectal cancerâ€•by Beaulieu JF. Gut, 2018, 67, 2227-2228.	12.1	3
9	A dietary flavone confers communicable protection against colitis through NLRP6 signaling independently of inflammasome activation. Mucosal Immunology, 2018, 11, 811-819.	6.0	55
10	Card9 mediates susceptibility to intestinal pathogens through microbiota modulation and control of bacterial virulence. Gut, 2018, 67, 1836-1844.	12.1	38
11	Proteasomal degradation of NOD2 by NLRP12 in monocytes promotes bacterial tolerance and colonization by enteropathogens. Nature Communications, 2018, 9, 5338.	12.8	44
12	MAVS deficiency induces gut dysbiotic microbiota conferring a proallergic phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10404-10409.	7.1	14
13	The NLRP6 Inflammasome Recognizes Lipoteichoic Acid and Regulates Gram-Positive Pathogen Infection. Cell, 2018, 175, 1651-1664.e14.	28.9	195
14	Understanding the Cellular Origin of the Mononuclear Phagocyte System Sheds Light on the Myeloid Postulate of Immune Paralysis in Sepsis. Frontiers in Immunology, 2018, 9, 823.	4.8	18
15	Implication of NOD-1 receptor in an experimental house dust mite-induced asthma model. , 2018, , .		0
16	Effects of enteral polymeric diet on gut microbiota in children with Crohn's disease. Gut, 2017, 66, 194-195.	12.1	19
17	Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. OncoImmunology, 2017, 6, e1132137.	4.6	45
18	LppM impact on the colonization of macrophages byMycobacterium tuberculosis. Cellular Microbiology, 2017, 19, e12619.	2.1	10

#	Article	IF	Citations
19	The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?. Therapie, 2017, 72, 21-38.	1.0	28
20	Hemidesmosome integrity protects the colon against colitis and colorectal cancer. Gut, 2017, 66, 1748-1760.	12.1	84
21	Genetic Factors Interact With Tobacco Smoke to Modify Risk for Inflammatory Bowel Disease in Humans and Mice. Gastroenterology, 2017, 153, 550-565.	1.3	68
22	Type I interferons drive inflammasome-independent emergency monocytopoiesis during endotoxemia. Scientific Reports, 2017, 7, 16935.	3.3	13
23	Keeping the (S)toolbox Alive Outside of the Body for Drugs Discovery. Gastroenterology, 2017, 153, 1689-1691.	1.3	0
24	The battlefield in the war against attaching-and-effacing bacterial pathogens: Monocytes, macrophages and dendritic cells in action. Veterinary Microbiology, 2017, 202, 47-51.	1.9	2
25	STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. Scientific Reports, 2016, 6, 29297.	3.3	64
26	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. American Journal of Human Genetics, 2016, 98, 857-868.	6.2	21
27	Nod2-mediated recognition of the microbiota is critical for mucosal adjuvant activity of cholera toxin. Nature Medicine, 2016, 22, 524-530.	30.7	94
28	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 2016, 45, 931-943.	14.3	645
29	Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. Cancer Research, 2016, 76, 4602-4607.	0.9	92
30	Epithelial IL-23R Signaling Licenses Protective IL-22 Responses in Intestinal Inflammation. Cell Reports, 2016, 16, 2208-2218.	6.4	89
31	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity, 2016, 44, 1255-1269.	14.3	797
32	NOD2 gene variant is a risk factor forÂpostoperative complications inÂpatients with Crohn's disease: AÂgenetic association study. Surgery, 2016, 160, 74-80.	1.9	13
33	Defining dysbiosis threatens Koch's postulates and current dogma on the role of Paneth cells in Crohn's disease. Gut, 2016, 65, 190-191.	12.1	2
34	Dysbiotic gut microbiota causes transmissible Crohn's disease-like ileitis independent of failure in antimicrobial defence. Gut, 2016, 65, 225-237.	12.1	317
35	Photodynamic Therapy Relieves Colitis and Prevents Colitis-associated Carcinogenesis in Mice. Inflammatory Bowel Diseases, 2015, 21, 985-995.	1.9	12
36	Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation. Journal of Molecular Cell Biology, 2015, 7, 351-365.	3.3	94

#	Article	IF	Citations
37	CARD8 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. Digestive and Liver Disease, 2015, 47, 938-942.	0.9	14
38	Time for epithelial sensing of vitamin D to step into the limelight. Gut, 2015, 64, 1013-1014.	12.1	5
39	Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth. Nature Cell Biology, 2015, 17, 1062-1073.	10.3	154
40	Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions. Expert Review of Clinical Immunology, 2015, 11, 637-657.	3.0	43
41	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 2015, 350, 1079-1084.	12.6	2,539
42	Gut microbiome and anticancer immune response: really hot Sh*t!. Cell Death and Differentiation, 2015, 22, 199-214.	11.2	100
43	Pancreatitis-Associated Protein Does Not Predict Disease Relapse in Inflammatory Bowel Disease Patients. PLoS ONE, 2014, 9, e84957.	2.5	7
44	CCL17 Production by Dendritic Cells Is Required for NOD1-mediated Exacerbation of Allergic Asthma. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 899-908.	5.6	28
45	Colonic Expression of the Peptide Transporter PEPT1 Is Downregulated During Intestinal Inflammation and Is Not Required for NOD2-dependent Immune Activation. Inflammatory Bowel Diseases, 2014, 20, 671-684.	1.9	31
46	Toll-interacting Protein Modulates Colitis Susceptibility in Mice. Inflammatory Bowel Diseases, 2014, 20, 660-670.	1.9	28
47	Decoding Norovirus Infection in CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2014, 20, 767-770.	1.9	13
48	Pseudomonas aeruginosa Type-3 Secretion System Dampens Host Defense by Exploiting the NLRC4-coupled Inflammasome. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 799-811.	5.6	90
49	Phagocytes Migration in Response to an Emergency Call From the Microbiota. Gastroenterology, 2013, 145, 1150-1151.	1.3	0
50	The peptide transporter PEPT1 is expressed in distal colon in rodents and humans and contributes to water absorption. American Journal of Physiology - Renal Physiology, 2013, 305, G66-G73.	3.4	40
51	Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut, 2013, 62, 1714-1723.	12.1	194
52	Looking beyond histological healing in ulcerative colitis: towards the establishment of a molecular signature for quiescent but progressive disease. Gut, 2013, 62, 959-960.	12.1	6
53	Enterocyte loss of polarity and gut wound healing rely upon the F-actinâ€“severing function of villin. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1380-9.	7.1	67
54	NOD2 prevents emergence of disease-predisposing microbiota. Gut Microbes, 2013, 4, 353-356.	9.8	10

#	Article	IF	Citations
55	NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. Journal of Clinical Investigation, 2013, 123, 700-11.	8.2	444
56	Intestinally Secreted C-Type Lectin Reg3b Attenuates Salmonellosis but Not Listeriosis in Mice. Infection and Immunity, 2012, 80, 1115-1120.	2.2	91
57	P095 Neutralizing responsiveness to Interleukin-33 abrogat1es experimental colitis through enhanced mucosal wound healing. Cytokine, 2012, 59, 549.	3.2	0
58	Usefulness of Serum and Faecal Pancreatitis-Associated Protein Dosage to Predict Disease Relapse in Inflammatory Bowel Disease Patients. Gastroenterology, 2011, 140, S-446.	1.3	0
59	Early Involvement of Liver Natural Killer T Cells in Limiting Colonic Inflammation and Application to Disease Treatment. Gastroenterology, 2011, 140, S-1.	1.3	1
60	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics, 2011, 43, 246-252.	21.4	1,201
61	Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9601-9606.	7.1	315
62	Defensins couple dysbiosis to primary immunodeficiency in Crohnâ€™s disease. World Journal of Gastroenterology, 2011, 17, 567.	3.3	16
63	Longest Form of CCTG Microsatellite Repeat in the Promoter of the CD2BP1/PSTPIP1 Gene Is Associated with Aseptic Abscesses and with Crohn Disease in French Patients. Digestive Diseases and Sciences, 2010, 55, 1681-1688.	2.3	47
64	Familial aggregation and antimicrobial response dose-dependently affect the risk for CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2010, 16, 58-67.	1.9	34
65	Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8772-8777.	7.1	183
66	Remote Control of Intestinal Tumorigenesis by Innate Immunity. Cancer Research, 2010, 70, 1749-1752.	0.9	12
67	Lessons from the inflammasome: a molecular sentry linking Candida and Crohn's disease. Trends in Immunology, 2010, 31, 171-175.	6.8	34
68	Debugging the intestinal microbiota in IBD. Gastroenterologie Clinique Et Biologique, 2009, 33, S131-S136.	0.9	4
69	Intestinal Microbiota Gives a Nod to the Hygiene Hypothesis in Type 1 Diabetes. Gastroenterology, 2009, 137, 381-383.	1.3	10
70	Candida albicans Colonization and ASCA in Familial Crohn's Disease. American Journal of Gastroenterology, 2009, 104, 1745-1753.	0.4	172
71	Toll-like receptor 2 is critical for induction of Reg3Â expression and intestinal clearance of Yersinia pseudotuberculosis. Gut, 2009, 58, 771-776.	12.1	93
72	Genetic Variants of Wnt Transcription Factor TCF-4 (TCF7L2) Putative Promoter Region Are Associated with Small Intestinal Crohn's Disease. PLoS ONE, 2009, 4, e4496.	2.5	125

#	Article	IF	Citations
73	NOD2: a potential target for regulating liver injury. Laboratory Investigation, 2008, 88, 318-327.	3.7	41
74	Detection of Antisynthetic Mannoside Antibodies (AÎ£MA) Reveals Heterogeneity in the ASCA Response of Crohn's Disease Patients and Contributes to Differential Diagnosis, Stratification, and Prediction. American Journal of Gastroenterology, 2008, 103, 949-957.	0.4	25
75	Innate Immunity in Crohn's Disease. Journal of Clinical Gastroenterology, 2008, 42, S144-S147.	2.2	23
76	NLRs: a Cytosolic Armory of Microbial Sensors Linked to Human Diseases. Nucleic Acids and Molecular Biology, 2008, , 169-185.	0.2	0
77	Â-Opioid receptor activation prevents acute hepatic inflammation and cell death. Gut, 2007, 56, 974-981.	12.1	27
78	Invited review: NOD2 and defensins: translating innate to adaptive immunity in Crohn's disease. Journal of Endotoxin Research, 2007, 13, 135-139.	2.5	19
79	Vascular and Cellular Stress in Inflammatory Bowel Disease: Revisiting the Role of Homocysteine. American Journal of Gastroenterology, 2007, 102, 1108-1115.	0.4	49
80	Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?. Gut, 2007, 56, 577-583.	12.1	200
81	[30] INVOLVEMENT OF NOD SIGNALLING IN HEPATOCYTE AND IMMUNE CELLS DURING HEPATITIS. Journal of Hepatology, 2007, 46, S15.	3.7	0
82	Prevention and Treatment of Colitis With Lactococcus lactis Secreting the Immunomodulatory Yersinia LcrV Protein. Gastroenterology, 2007, 133, 862-874.	1.3	108
83	IBD serological panels: Facts and perspectives. Inflammatory Bowel Diseases, 2007, 13, 1561-1566.	1.9	75
84	How NOD2 mutations predispose to Crohn's disease?. Microbes and Infection, 2007, 9, 658-663.	1.9	34
85	Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nature Medicine, 2007, 13, 35-37.	30.7	734
86	Nod-Like Receptors: Cytosolic Watchdogs for Immunity against Pathogens. PLoS Pathogens, 2007, 3, e152.	4.7	53
87	Advances and Perspectives in the Genetics of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2006, 4, 143-151.	4.4	29
88	NODs in defence: from vulnerable antimicrobial peptides to chronic inflammation. Trends in Microbiology, 2006, 14, 432-438.	7.7	44
89	Microbial induction of CARD15 expression in intestinal epithelial cells via tollâ€like receptor 5 triggers an antibacterial response loop. Journal of Cellular Physiology, 2006, 209, 241-252.	4.1	53
90	PPARÂ as a new therapeutic target in inflammatory bowel diseases. Gut, 2006, 55, 1341-1349.	12.1	363

#	Article	IF	Citations
91	Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut, 2006, 55, 815-823.	12.1	80
92	Specific Recognition of Candida albicans by Macrophages Requires Galectin-3 to Discriminate Saccharomyces cerevisiae and Needs Association with TLR2 for Signaling. Journal of Immunology, 2006, 177, 4679-4687.	0.8	214
93	Early-onset sarcoidosis gets the nod. Blood, 2005, 105, 912-912.	1.4	3
94	A Novel Caspase-1/Toll-like Receptor 4-independent Pathway of Cell Death Induced by Cytosolic Shigella in Infected Macrophages. Journal of Biological Chemistry, 2005, 280, 14042-14050.	3.4	51
95	Nod2-Dependent Regulation of Innate and Adaptive Immunity in the Intestinal Tract. Science, 2005, 307, 731-734.	12.6	1,643
96	NOD-LRR PROTEINS: Role in Host-Microbial Interactions and Inflammatory Disease. Annual Review of Biochemistry, 2005, 74, 355-383.	11.1	871
97	Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO Journal, 2004, 23, 1587-1597.	7.8	325
98	Battling enteroinvasive bacteria: Nod1 comes to the rescue. Trends in Microbiology, 2004, 12, 529-532.	7.7	20
99	Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cellular Microbiology, 2003, 5, 581-592.	2.1	309
100	Clustering of Crohn's disease within affected sibships. European Journal of Human Genetics, 2003, 11, 179-184.	2.8	28
101	An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nature Immunology, 2003, 4, 702-707.	14.5	1,139
102	Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3455-3460.	7.1	288
103	Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. Gut, 2003, 52, 840-846.	12.1	130
104	Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection. Journal of Biological Chemistry, 2003, 278, 8869-8872.	3.4	2,026
105	CARD4/NOD1 is not involved in inflammatory bowel disease. Gut, 2003, 52, 71-74.	12.1	57
106	CARD15/NOD2 Mutational Analysis and Genotype-Phenotype Correlation in 612 Patients with Inflammatory Bowel Disease. American Journal of Human Genetics, 2002, 70, 845-857.	6.2	943
107	CARD15 mutations in Blau syndrome. Nature Genetics, 2001, 29, 19-20.	21.4	915
108	Genetic refinement and physical mapping of a chromosome 16q candidate region for inflammatory bowel disease. European Journal of Human Genetics, 2001, 9, 731-742.	2.8	10

#	Article	IF	Citations
109	Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature, 2001, 411, 599-603.	27.8	5,088